Cyclooxygenase-2 expression in gastrointestinal stromal tumours

Sevinç, Alper; Camcı, Celalettin; Sarı, İsmail; Kalender, Mehmet; Er, Özlem; Soyuer, Işın; Dikilitaş, Mustafa; Yılmaz, Ümit; Sağol, Özgül; Alacacıoğlu, Ahmet

doi:10.1200/jco.2008.26.15_suppl.15643

Cited by 3 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study by Sevinc et al investigated cyclooxygenase 2 (COX-2) expression in GIST. Their findings demonstrated that use of Cox-2 inhibitors, with or without Tyrosine Kinase inhibitors, may be helpful in the adjuvant setting in preventing or delaying recurrence (Sevinc et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal Stromal Tumors: A Clinicopathologic and Risk Stratification Study of 255 Cases from Pakistan and Review of Literature

Din¹,

Ahmad²,

Arshad³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: To describe the clinicopathological features of gastrointestinal stromal tumors (GIST) diagnosed in our section and to perform risk stratification of our cases by assigning them to specific risk categories and groups for disease progression based on proposals by Fletcher et al and Miettinen and Lasota. Materials and Results: We retrieved 255 cases of GIST diagnosed between 2003 and 2014. Over 59% were male. The age range was 16 to 83 years with a mean of 51 years. Over 70% occurred between 40 and 70 years of age. Average diameter of tumors was 10 cms. The stomach was the most common site accounting for about 40%. EGISTs constituted about 16%. On histologic examination, spindle cell morphology was seen in almost of 85% cases. CD117 was the most useful immunohistochemical antibody, positive in 98%. Risk stratification was possible for 220 cases. Based on Fletcher's consensus proposal, 62.3 gastric, 81.8% duodenal, 68% small intestinal, 72% colorectal and 89% EGISTs were assigned to the high risk category; while based on Miettinen and Lasota's algorithm, about 48% gastric, 100% duodenal, 76% small intestinal, 100% colorectal and 100% EGISTs in our study were associated with high risk for disease progression, tumor metastasis and tumor related death. Follow up was available in 95 patients; 26 were dead and 69 alive at follow up. Most of the patients who died had high risk disease and on average death occurred just a few months to a maximum of one to two years after initial surgical resection. Conclusions: Epidemiological and morphologic findings in our study were similar to international published data. The majority of cases in our study belonged to the high risk category.

show abstract

Section: Discussionmentioning

confidence: 99%

Gastrointestinal Stromal Tumors: A Clinicopathologic and Risk Stratification Study of 255 Cases from Pakistan and Review of Literature

Din¹,

Ahmad²,

Arshad³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…In many cancers, the association of over-expression of COX-2 and tumor progression is established. Moreover, COX-2 expression may be correlated with cancer prognosis [ 32 ]. Therefore, COX-2 polymorphism has received widespread attention, and many meta-analyses have been reported to assess the relationship between the polymorphism and human cancers.…”

Section: Discussionmentioning

confidence: 99%

Lack of association between COX-2 8473T>C polymorphism and breast cancer risk: a meta-analysis

Jiang

Quan

Zhang

et al. 2014

View full text Add to dashboard Cite

Aim of the studyResults of recent published studies on the association between the COX-2 8473T>C polymorphism and the risk of breast cancer have often been conflicting. To make a more precise estimation of the potential relationship, a meta-analysis was performed.Material and methodsA total of seven case-control studies with 7,033 cases and 9,350 controls were included in the current meta-analysis through searching the databases of PubMed, Embase, and Cochrane Library (up to March 1st, 2013). The odds ratio (OR) and 95% confidence interval (95% CI) were calculated to assess the strength of the association. The meta-analysis was conducted in a fixed/random effect model.ResultsWe found no significant associations for all genetic models after all studies were pooled into the meta-analysis (for C vs. T: OR = 0.974, 95% CI: 0.906–1.047, p = 0.471; for CC vs. TT: OR = 0.957, 95% CI: 0.803–1.140, p = 0.62; for TC vs. TT: OR = 0.964, 95% CI: 0.881–1.055, p = 0.421; for CC + TC vs. TT: OR = 0.963, 95% CI: 0.880–1.053, p = 0.406; for CC vs. TT + TC: OR = 0.978, 95% CI: 0.831–1.15, p = 0.788). We also observed no obvious associations in the subgroup analyses by ethnicity (Caucasian) and source of controls (population based, PB) for all genetic models.ConclusionsCurrent evidence suggests that the COX-2 8473T>C polymorphism is not associated with breast cancer risk.

show abstract

“…Medical oncologists are divided into two groups according to the cancer type they are treating: Oncologists and OncoloGISTs. Every patient with GIST is a new experience for a medical oncoloGIST [17][18][19][20][21][22] .…”

Section: Discussionmentioning

confidence: 99%

‘Time Is a GIFT in GIST’ – The Medical and Paramedical Perspective of a Case with Metastatic Gastrointestinal Stromal Tumor

Sevinç

Camcı²

2008

Chemotherapy

View full text Add to dashboard Cite

Few recent developments in oncology have generated comparable interest as have the dramatic successes in the therapy of gastrointestinal stromal tumors (GIST) with imatinib mesylate. Imatinib, a selective tyrosine kinase inhibitor, is currently the standard of care first-line treatment for unresectable or metastatic GIST, improving survival time and delaying disease progression. The authors report a 50-year-old male patient referred as relapsed chemotherapy-resistant CD117– leiomyosarcoma. After learning about the failure of chemotherapy, the patient became depressive and considered committing a suicide. We performed a second CD117 staining. As the second analysis was found to be positive, the diagnosis of leiomyosarcoma was changed to GIST. Imatinib 600 mg/day was started. The result with imatinib was appraised as a partial response/stable disease after the chemotherapy failure. The patient‘s depressive mood was also improved after imatinib. The medical and paramedical perspectives of the case are presented to emphasize the importance of immunohistochemical staining and its inhibition by a novel tyrosine kinase inhibitor in GIST. All nonepithelial tumors, particularly nonepithelial abdominal tumors of leiomyoblastic appearance should be considered to be GIST unless an experienced pathologist who does CD117 staining routinely confirms a different diagnosis. Interestingly, depression due to chemotherapy failure was also alleviated with imatinib. According to a recent study, median time to progression was 24 months, and overall survival was 57 months, reaching 5 years with imatinib. Conclusion: time is a GIFT in GIST.

show abstract

Cyclooxygenase-2 expression in gastrointestinal stromal tumours

Cited by 3 publications

References 9 publications

Gastrointestinal Stromal Tumors: A Clinicopathologic and Risk Stratification Study of 255 Cases from Pakistan and Review of Literature

Gastrointestinal Stromal Tumors: A Clinicopathologic and Risk Stratification Study of 255 Cases from Pakistan and Review of Literature

Lack of association between COX-2 8473T>C polymorphism and breast cancer risk: a meta-analysis

‘Time Is a GIFT in GIST’ – The Medical and Paramedical Perspective of a Case with Metastatic Gastrointestinal Stromal Tumor

Contact Info

Product

Resources

About